GlobeNewswire

Media Advisory: Bombardier to report Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019

Share

MONTREAL, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) will publish its financial results for the fourth quarter and full year 2018 on Thursday, February 14, 2019, and will hold a live webcast/conference call to review the results starting at 8 a.m. Eastern Time (EST). A press release including the financial results will be issued prior to the call.

Alain Bellemare, President and Chief Executive Officer; John Di Bert, Senior Vice President and Chief Financial Officer; and Patrick Ghoche, Vice President, Investor Relations will present a review of the company’s financial results for the quarter and full year during the call intended for investors and financial analysts.

  DATE: Thursday, February 14, 2019
     
  TIME: 8:00 a.m., EST

The live webcast and relevant financial charts will be available at ir.bombardier.com.

Stakeholders who wish to listen to the presentation and question and answer period by telephone may dial one of the following conference call numbers:

In English: 514-394-9320 or
  1-866-240-8954 (toll-free in North America)
  +800 6578 9868 (overseas calls)
   
In French: 514-394-9316 or
(with translation) 1-888-791-1368 (toll-free in North America)
  +800 6578 9868 (overseas calls)

The replay of this conference call will be available on Bombardier’s website shortly after the end of the webcast.

For Information  
Simon Letendre Patrick Ghoche
Manager, Media Relations and Public Affairs Vice President, Investor Relations
Bombardier Inc. Bombardier Inc.
+1 514 861 9481 +1 514 861 5727

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPress release

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED19.7.2019 12:00:00 CESTPress release

Rapala VMC Corporation Half year financial report July 19, 2019 at 1:00 p.m. RAPALA VMC CORPORATION’S HALF YEAR REPORT H1/2019: SALES AND PROFITABILITY DECREASED FROM LAST YEAR – FULL YEAR GUIDANCE UNCHANGED January-June (H1) in brief: Net sales were 141.2 MEUR, down 1% from previous year (142.5). With comparable exchange rates sales were 2% lower than last year. Operating profit was 11.4 MEUR (15.3), down 25%.1) Comparable operating profit* was 12.0 MEUR (15.2), down 21%. 1) Cash flow from operations was 11.5 MEUR (5.9). 2) Earnings per share was 0.17 EUR (0.23), down 26%. Full year guidance unchanged: Full year net sales with comparable FX rates expected to be around last year’s level and comparable operating profit* to increase from last year. Strong second half of the year expected: record strong order book in North America, improvements in Indonesian lure factory combined with rigorous management of fixed costs. Uncertainties and risks relate to US-China trade relations, global ec

Scientific Beta defends the role of the Size factor in multi-factor portfolios19.7.2019 11:32:00 CESTPress release

Scientific Beta defends the role of the Size factor in multi-factor portfolios Research shows that omitting the Size factor would be costly for investors New research from Scientific Beta, the smart beta index provider, has shown that the Size factor improves model fit, delivers a significant positive premium in the presence of other factors, and contributes positively to the performance of multi-factor portfolios. The Size effect is well established in the finance literature: stocks with smaller market capitalisation outperform large stocks over the long term. However, a common recommendation in the asset management industry is to remove Size from the factor menu, given its relatively weak post-publication performance. Scientific Beta's analysis differs from recent studies by smart beta providers in assessing the relevance of the Size factor. Rather than asking which factor has the best stand-alone performance, we ask what the marginal impact of the Size factor is when including it in